{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T04:56:10Z","timestamp":1790571370526,"version":"4.1.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study aimed to compare the effects of various first-line systemic therapies on health-related quality of life (HR-QoL) in patients with unresectable advanced gastric cancer (GC), and to comprehensively integrate survival benefits and HR-QoL outcomes associated with different treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic literature search was conducted in the MEDLINE, CENTRAL and Scopus databases for studies published from database inception to December 2025. Manual retrieval of reference lists and abstracts from major oncology conferences held between 2016 and 2025 was performed as supplementary screening. Eligible studies were phase III randomized controlled trials (RCTs) that compared immune checkpoint inhibitors or targeted agents with platinum-based chemotherapy as first-line regimens for advanced GC and reported data on HR-QoL deterioration. Time to deterioration (TTD) of HR-QoL domains was assessed using the EORTC QLQ-C30, EORTC QLQ-STO22 and EQ-5D questionnaires. The surface under the cumulative ranking curve (SUCRA) was applied to rank all included treatments based on HR-QoL indicators. We further performed an exploratory composite analysis integrating overall-survival and HR-QoL outcomes via the minimum distance criterion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 10 RCTs enrolling over 8000 patients and covering six HR-QoL domains met the inclusion criteria. SUCRA analyses indicated that trastuzumab and tislelizumab had the lowest probability of the deterioration of global health status, physical function, nausea\/vomiting, appetite loss and pain. When HR-QoL was combined with overall survival (OS) via an exploratory minimum distance criterion composite analysis, trastuzumab and tislelizumab showed favorable comprehensive performance across most evaluated domains. This composite metric remains exploratory without established uncertainty estimates and should not serve as primary evidence for clinical decision-making.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This network meta-analysis suggests that trastuzumab (for HER2-positive disease) and tislelizumab (for largely biomarker-unselected populations) deliver the balance between HR-QoL preservation and OS benefit within their respective biomarker-eligible patient subgroups among systemic treatment options for unresectable advanced GC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n                      , identifier CRD420261422326.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1910817","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T04:28:47Z","timestamp":1790569727000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrating overall survival and health-related quality of life to prioritize first-line systemic therapies for unresectable advanced gastric cancer: a network meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Ji","family":"Wu","sequence":"first","affiliation":[{"name":"Department of General surgery, Suzhou Ninth Hospital Affiliated to Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Interventional Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiping","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of General surgery, Suzhou Ninth Hospital Affiliated to Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yefeng","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of General surgery, Suzhou Ninth Hospital Affiliated to Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01654-2","article-title":"Helicobacter pylori and gastric cancer: mechanisms and new perspectives","volume":"18","author":"Duan","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)00052-2","article-title":"Gastric cancer","volume":"405","author":"Sundar","year":"2025","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13045-023-01451-3","article-title":"Gastric cancer treatment: recent progress and future perspectives","volume":"16","author":"Guan","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.948647","article-title":"Recent progress and future perspectives of immunotherapy in advanced gastric cancer","volume":"13","author":"Jin","year":"2022","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1158\/2159-8290.Cd-21-0888","article-title":"Early tumor-immune microenvironmental remodeling and response to first-line fluoropyrimidine and platinum chemotherapy in advanced gastric cancer","volume":"12","author":"Kim","year":"2022","journal-title":"Cancer Discov"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.01601","article-title":"First-line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-year follow-up of the phase III CheckMate 649 trial","volume":"42","author":"Janjigian","year":"2024","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(23)00541-7","article-title":"Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study","volume":"25","author":"Shitara","year":"2024","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01773-9","article-title":"First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study","volume":"9","author":"Chen","year":"2024","journal-title":"Signal Transduction Targeted Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2024.5624","article-title":"HER2(+) advanced gastric cancer: Current state and opportunities (Review)","volume":"64","author":"Hu","year":"2024","journal-title":"Int J Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.20034","article-title":"Gastric cancer: A review","volume":"335","author":"Patel","year":"2026","journal-title":"Jama"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.2470","article-title":"Integrating quality of life and survival in systemic therapy for advanced hepatocellular carcinoma: A network meta-analysis","volume":"11","author":"Celsa","year":"2025","journal-title":"JAMA Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw258","article-title":"A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)","volume":"28","author":"Cherny","year":"2017","journal-title":"Ann Oncol Off J Eur Soc For Med Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2024.1210","article-title":"Quality of life and nutritional outcomes of stomach-preserving surgery for early gastric cancer: A secondary analysis of the SENORITA randomized clinical trial","volume":"159","author":"Eom","year":"2024","journal-title":"JAMA Surg"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115807","article-title":"First-line pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: Health-related quality of life from the randomized phase III KEYNOTE-859 trial","volume":"231","author":"Lowery","year":"2025","journal-title":"Eur J Cancer (Oxford Engl 1990)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-022-06562-5","article-title":"Overall survival advantage of omentum preservation over omentectomy for advanced gastric cancer: A systematic review and meta-analysis","volume":"46","author":"Kong","year":"2022","journal-title":"World J Surg"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1564604","article-title":"First-line immune checkpoint inhibitors with chemotherapy in advanced gastric and gastroesophageal junction adenocarcinoma: a meta-analysis of phase 3 trials","volume":"16","author":"Lin","year":"2025","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1566939","article-title":"The efficacy and safety of PD-1\/PD-L1 inhibitors in combination with chemotherapy as a first-line treatment for unresectable, locally advanced, HER2-negative gastric or gastroesophageal junction cancer: a meta-analysis of randomized controlled trials","volume":"16","author":"Pu","year":"2025","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1500954","article-title":"Efficacy and safety of programmed cell death protein-1 inhibitor for first-line therapy of advanced gastric or gastroesophageal junction cancer: a network meta-analysis","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.7326\/m14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/bjsports-2019-100886","article-title":"Which specific modes of exercise training are most effective for treating low back pain? Network meta-analysis","volume":"54","author":"Owen","year":"2020","journal-title":"Br J Sports Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)01293-0","article-title":"The effects of antidepressants on cardiometabolic and other physiological parameters: a systematic review and network meta-analysis","volume":"406","author":"Pillinger","year":"2025","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13092080","article-title":"Patient-reported outcomes of regular aerobic exercise in gastric cancer","volume":"13","author":"Lee","year":"2021","journal-title":"Cancers"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-025-01660-4","article-title":"Comparative efficacy and safety of tislelizumab and other programmed cell death protein 1 inhibitors in first-line treatment of advanced gastroesophageal cancers: a systematic review and network meta-analysis","volume":"28","author":"Ajani","year":"2025","journal-title":"Gastric Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"22024","DOI":"10.1038\/s41598-022-24426-9","article-title":"Comparative efficacy and tolerability of targeted and immunotherapy combined with chemotherapy as first-line treatment for advanced gastric cancer: a Bayesian network meta-analysis","volume":"12","author":"Liu","year":"2022","journal-title":"Sci Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32020112","article-title":"Immunotherapy combined with chemotherapy in the first-line treatment of advanced gastric cancer: systematic review and Bayesian network meta-analysis based on specific PD-L1 CPS","volume":"32","author":"Zhang","year":"2025","journal-title":"Curr Oncol (Toronto Ont)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03415-0","article-title":"Tislelizumab\u2009+\u2009chemotherapy in gastric cancer: long-term RATIONALE-305 randomized trial follow-up","volume":"43","author":"Cruz-Correa","year":"2026","journal-title":"Adv Ther"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0058","article-title":"Quality of life in the trastuzumab for gastric cancer trial","volume":"19","author":"Satoh","year":"2014","journal-title":"Oncologist"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00692-6","article-title":"Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Kang","year":"2022","journal-title":"Lancet Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.00170","article-title":"Health-related quality of life with nivolumab plus chemotherapy versus chemotherapy in patients with advanced gastric\/gastroesophageal junction cancer or esophageal adenocarcinoma from CheckMate 649","volume":"41","author":"Moehler","year":"2023","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100189","article-title":"Quality of life with first-line pembrolizumab for PD-L1-positive advanced gastric\/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study","volume":"6","author":"Van Cutsem","year":"2021","journal-title":"ESMO Open"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(10)61121-x","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1177\/1758834012469429","article-title":"Gastric cancer and trastuzumab: first biologic therapy in gastric cancer","volume":"5","author":"Gunturu","year":"2013","journal-title":"Ther Adv Med Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1177\/10732748221111296","article-title":"Tislelizumab: a modified anti-tumor programmed death receptor 1 antibody","volume":"29","author":"Zhang","year":"2022","journal-title":"Cancer Control J Moffitt Cancer Center"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105542","article-title":"Pembrolizumab with trastuzumab and chemotherapy for HER2-positive advanced gastric cancer: health-related quality-of-life analysis from the randomized KEYNOTE-811 trial","volume":"10","author":"Janjigian","year":"2025","journal-title":"ESMO Open"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006500","article-title":"Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review","volume":"11","author":"Barron","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103663","article-title":"Health-related quality of life in patients with CLDN18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: results from the SPOTLIGHT and GLOW clinical trials","volume":"9","author":"Lordick","year":"2024","journal-title":"ESMO Open"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1644263","article-title":"Case report: Zolbetuximab-induced gastritis with protein-losing gastroenteropathy and hypogammaglobulinemia: a case implicating IgA vasculitis","volume":"15","author":"Mitsui","year":"2025","journal-title":"Front Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105805","article-title":"Characterization of early-onset gastritis during zolbetuximab-containing chemotherapy in CLDN18.2-positive gastric cancer","volume":"10","author":"Yamamoto","year":"2025","journal-title":"ESMO Open"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1910817\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T04:28:48Z","timestamp":1790569728000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1910817\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":40,"alternative-id":["10.3389\/fonc.2026.1910817"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1910817","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"article-number":"1910817"}}